Xu Diyong 4

What Happened

• Xu Diyong, a reported 10% owner of Q32 Bio (QTTB), received a derivative award on June 12, 2026 covering 9,810 shares. The award is reported at $0.00 (no cash paid at grant) and is structured as options that will vest and become exercisable in full on the earlier of June 12, 2027 or the issuer’s next annual meeting, subject to Xu’s continued service.
• Per the filing, Xu is obligated under an agreement to transfer any securities issued under these options—or the economic benefit thereof—to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure the securities/economic benefits are provided to OrbiMed Private Investments VII, LP. This indicates the award is intended for an OrbiMed fund rather than reflecting a direct personal purchase.

Key Details

• Transaction date: 2026-06-12; filing date: 2026-06-16 (filed within the Form 4 two-business-day window).
• Transaction type: Grant/award of a derivative security (code A); 9,810 shares at $0.00.
• Vesting/exercise: Vests and becomes exercisable in full on earlier of 6/12/2027 or the next annual meeting, subject to continued service (Footnote F1).
• Transfer obligation: Award/securities or their economic benefit will be transferred to OrbiMed Advisors LLC / OrbiMed Capital GP VII LLC for OrbiMed Private Investments VII, LP (Footnote F2).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• This was a derivative award (options) rather than an open-market buy or sale—no shares were sold and no cash was exchanged at grant; the award vests in the future and must be exercised to convert to shares.
• Because the award is to be transferred to an institutional investor (OrbiMed fund) and Xu is a 10% owner, this appears to be an allocation tied to institutional arrangements rather than a personal trading signal.